Literature DB >> 34919142

Targeting nicotinamide adenosine dinucleotide (NAD) in diffuse gliomas.

Jing Wu1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2022        PMID： 34919142      PMCID： PMC8804876          DOI： 10.1093/neuonc/noab265

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN： 1522-8517            Impact factor:   12.300


× No keyword cloud information.
  10 in total

Review 1.  NAD metabolism: Implications in aging and longevity.

Authors:  Keisuke Yaku; Keisuke Okabe; Takashi Nakagawa
Journal:  Ageing Res Rev       Date:  2018-06-05       Impact factor: 10.895

Review 2.  Targeting metabolic pathways for head and neck cancers therapeutics.

Authors:  Masashi Yamamoto; Hidenori Inohara; Takashi Nakagawa
Journal:  Cancer Metastasis Rev       Date:  2017-09       Impact factor: 9.264

Review 3.  The NAD metabolome--a key determinant of cancer cell biology.

Authors:  Alberto Chiarugi; Christian Dölle; Roberta Felici; Mathias Ziegler
Journal:  Nat Rev Cancer       Date:  2012-09-28       Impact factor: 60.716

4.  Loss of NAPRT1 expression by tumor-specific promoter methylation provides a novel predictive biomarker for NAMPT inhibitors.

Authors:  David S Shames; Kristi Elkins; Kimberly Walter; Thomas Holcomb; Pan Du; Dane Mohl; Yang Xiao; Thinh Pham; Peter M Haverty; Bianca Liederer; Xiaorong Liang; Robert L Yauch; Thomas O'Brien; Richard Bourgon; Hartmut Koeppen; Lisa D Belmont
Journal:  Clin Cancer Res       Date:  2013-10-04       Impact factor: 12.531

5.  Safety and efficacy of NAD depleting cancer drugs: results of a phase I clinical trial of CHS 828 and overview of published data.

Authors:  Anne von Heideman; Ake Berglund; Rolf Larsson; Peter Nygren
Journal:  Cancer Chemother Pharmacol       Date:  2009-09-30       Impact factor: 3.333

6.  The pharmacokinetics, toxicities, and biologic effects of FK866, a nicotinamide adenine dinucleotide biosynthesis inhibitor.

Authors:  Kyle Holen; Leonard B Saltz; Ellen Hollywood; Konrad Burk; Axel-Rainer Hanauske
Journal:  Invest New Drugs       Date:  2007-10-09       Impact factor: 3.850

7.  Extreme Vulnerability of IDH1 Mutant Cancers to NAD+ Depletion.

Authors:  Kensuke Tateishi; Hiroaki Wakimoto; A John Iafrate; Shota Tanaka; Franziska Loebel; Nina Lelic; Dmitri Wiederschain; Olivier Bedel; Gejing Deng; Bailin Zhang; Timothy He; Xu Shi; Robert E Gerszten; Yiyun Zhang; Jing-Ruey J Yeh; William T Curry; Dan Zhao; Sudhandra Sundaram; Fares Nigim; Mara V A Koerner; Quan Ho; David E Fisher; Elisabeth M Roider; Lajos V Kemeny; Yardena Samuels; Keith T Flaherty; Tracy T Batchelor; Andrew S Chi; Daniel P Cahill
Journal:  Cancer Cell       Date:  2015-12-14       Impact factor: 31.743

8.  FK866, a highly specific noncompetitive inhibitor of nicotinamide phosphoribosyltransferase, represents a novel mechanism for induction of tumor cell apoptosis.

Authors:  Max Hasmann; Isabel Schemainda
Journal:  Cancer Res       Date:  2003-11-01       Impact factor: 12.701

Review 9.  Hallmarks of cancer: the next generation.

Authors:  Douglas Hanahan; Robert A Weinberg
Journal:  Cell       Date:  2011-03-04       Impact factor: 41.582

10.  Inhibition of nicotinamide phosphoribosyltransferase (NAMPT), the rate-limiting enzyme of the nicotinamide adenine dinucleotide (NAD) salvage pathway, to target glioma heterogeneity through mitochondrial oxidative stress.

Authors:  Pratibha Sharma; Jihong Xu; Katie Williams; Michelle Easley; J Brad Elder; Russell Lonser; Frederick F Lang; Rosa Lapalombella; Deepa Sampath; Vinay K Puduvalli
Journal:  Neuro Oncol       Date:  2022-02-01       Impact factor: 13.029
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.